The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for ...

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...

Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and ...

Biosimilar SB12 or Epysqli (eculizumab-aagh; Samsung Bioepis) is equivalent to reference eculizumab (Soliris) for treating complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria ...

Number 5: FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for affordability and policy reform. Number 4: Denosumab biosimilars Wyost and ...

Jeffrey Curtis, MD, MS, MPH, provides expert perspective for navigating the evolving treatment landscape of osteoporosis and key considerations for biologic and biosimilar utilization.

Sarfaraz K. Niazi, PhD, argues that the S-150 bill, also known as the "Affordable Prescriptions for Patients Act of 2023," aims to reduce drug prices by addressing anti-competitive practices, such as ...

Dive into biosimilar regulations in the US! Test your knowledge with our quiz on FDA rules, naming tricks, postmarket safety, and more. Ready for the challenge?